Clinical Trials Sponsored by SFA Therapeutics

Total 8904 results

SFA Therapeutics

Recruiting

Study of SFA002 in Patients With Mild to Moderate Psoriasis Plaques

Psoriasis

United States
ADC Therapeutics S.A.

Recruiting

A Study of Mipasetamab Uzoptirine (ADCT-601) in Participants With Solid Tumors

Advanced Solid Tumors

United States, United Kingdom, Spain, France
ADC Therapeutics S.A.

Recruiting

Study to Evaluate Loncastuximab Tesirine With Rituximab Versus Immunochemotherapy in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS 5)

Refractory Diffuse Large B-Cell Lymphoma | Relapsed Diffuse Large B-Cell Lymphoma

Japan, Belgium, France, Italy, Spain, United Kingdom, United States, Israel, Hungary, Brazil, Switzerland, Poland, Canada, Puerto Rico, Czechia, Netherlands, China, Mexico, Argentina, Chile, Turkey
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

Melanoma | Renal Cell Carcinoma | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Bladder Cancer | Non-small Cell Lung Cancer | Pancreas Cancer | Colo-rectal Cancer | Triple-negative Breast Cancer | Head and Neck Cancer Squamous Cell Carcinoma

United States, Belgium, United Kingdom
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma

Refractory Hodgkin Lymphoma | Relapsed Hodgkin Lymphoma

United States, Spain, United Kingdom, Poland, Belgium, Hungary, Germany, France, Italy, Czechia, Canada
ADC Therapeutics S.A.

Terminated

Safety and Efficacy Study of Loncastuximab Tesirine + Ibrutinib in Diffuse Large B-Cell or Mantle Cell Lymphoma

Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

United States, Spain, United Kingdom, France, Italy, Belgium
ADC Therapeutics S.A.

Terminated

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine Versus Idelalisib in Participants With Relapsed or Refractory Follicular Lymphoma (LOTIS-6)

Relapsed Follicular Lymphoma | Refractory Follicular Lymphoma

United States, Belgium, Hungary, Israel, Spain, Switzerland, Poland, France, United Kingdom, Italy
ADC Therapeutics S.A.

Completed

Study to Evaluate the Efficacy and Safety of Loncastuximab Tesirine in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (LOTIS-2)

Diffuse Large B-cell Lymphoma Recurrent | Diffuse Large B-Cell Lymphoma Refractory

United States, United Kingdom, Italy, Switzerland
Bone Therapeutics S.A

Completed

A Study on Visco-antalgic Intra-articular Administration in Symptomatic Knee Osteoarthritis

Knee Osteoarthritis
Bone Therapeutics S.A

Completed

Phase 2a Study on Allogeneic Osteoblastic Cells Implantation in Lumbar Spinal Fusion

Degenerative Disc Disease

Belgium
Bone Therapeutics S.A

Completed

A mRUS Validation Study for Nail-treated Fractures of Long Bones and a TUS Exploratory Study for Nail and Plate-treated Fractures of Long Bones (mRUSTUS)

Bone Fracture | Validation Studies | Fracture Healing | X-Ray | Delayed Union Fracture | CT-scan

Germany
ADC Therapeutics S.A.

Terminated

Safety, Tolerability, Pharmacokinetics, and Antitumor Study of ADCT-601 to Treat Advanced Solid Tumors

Advanced Solid Tumors

United States
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7)

B-Cell Non-Hodgkin Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Relapsed B-Cell Non-Hodgkin Lymphoma

United States, Spain, Italy, United Kingdom, Belgium, Czechia
ADC Therapeutics S.A.

Completed

A Study of Loncastuximab Tesirine and Rituximab (Lonca-R) in Previously Untreated Unfit/Frail Participants With Diffuse Large B-cell Lymphoma (DLBCL) (LOTIS-9)

Diffuse Large B-cell Lymphoma

Spain, United States, Italy, Puerto Rico
ADC Therapeutics S.A.

Withdrawn

Long-term Registry of Patients Treated With Loncastuximab Tesirine

B-Cell Lymphomas

United States
ADC Therapeutics S.A.

Withdrawn

A Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Antitumor Activity of Loncastuximab Tesirine in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated Diffuse Large B-cell Lymphoma (LOTIS-8) (LOTIS-8)

Diffuse Large B-Cell Lymphoma

United States
ADC Therapeutics S.A.

Terminated

Safety and Antitumor Activity Study of Loncastuximab Tesirine and Durvalumab in Diffuse Large B-Cell, Mantle Cell, or Follicular Lymphoma

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma

Spain, United States
ADC Therapeutics S.A.

Terminated

Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression

Breast Cancer | Non Small Cell Lung Cancer | Bladder Cancer | GastroEsophageal Cancer

United States, Belgium
Bone Therapeutics S.A

Terminated

Study on Autologous Osteoblastic Cells Implantation in Hypotrophic Non-Union Fractures

Long Bone Non-Union

Belgium, France, Netherlands
Bone Therapeutics S.A

Terminated

Study on Allogeneic Osteoblastic Cells Implantation in Rescue Interbody Fusion

Failed Lumbar Fusion

Belgium
ADC Therapeutics S.A.

Terminated

Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL)

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia

United States
ADC Therapeutics S.A.

Recruiting

A Study to Evaluate the Pharmacokinetics and Safety of Loncastuximab Tesirine in Participants With Relapsed or Refractory Diffuse Large B-cell Lymphoma or High-grade B-cell Lymphoma With Hepatic Impairment (LOTIS-10)

Diffuse Large B-Cell Lymphoma | High-grade B-cell Lymphoma

Taiwan, Korea, Republic of, United States, Brazil
ADC Therapeutics S.A.

Active, not recruiting

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of ADCT-901 in Participants With Selected Advanced Solid Tumors

Advanced Solid Tumors

United States, Spain, United Kingdom
Bone Therapeutics S.A

Terminated

Study on Autologous Osteoblastic Cells Implantation to Early Stage Osteonecrosis of the Femoral Head

Osteonecrosis of the Femoral Head
Bone Therapeutics S.A

Completed

Phase 1/2a Study on Allogeneic Osteoblastic Cells Implantation in Delayed-Union Fractures

Long Bone Delayed-Union Fracture
ADC Therapeutics S.A.

Completed

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

Hodgkin Lymphoma | Non-Hodgkin Lymphoma

United States, United Kingdom
ADC Therapeutics S.A.

Terminated

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Acute Lymphoblastic Leukemia (B-ALL)

Acute Lymphoblastic Leukemia

United States
ADC Therapeutics S.A.

Completed

Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Mantle-Cell | Waldenstrom Macroglobulinemia | Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma | Primary Mediastinal B-cell Lymphoma | Burkitt's Lymphoma | Lymphoma, Marginal Zone

United Kingdom, United States, Italy
ADC Therapeutics S.A.

No longer available

Loncastixumab Tesirine (ADCT-402) Expanded Access Program (EAP) for Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Relapsed or Refractory Diffuse Large B-Cell Lymphoma (R/R DLBCL)
Bone Therapeutics S.A

Terminated

Research Study on the Immunosuppressive Effects of a Cell Therapy Product on PBMC Isolated From Blood of Patients With Inflammatory Rheumatic Diseases

Rheumatoid Arthritis | Spondylarthritis | Psoriatic Arthritis
Endo Tools Therapeutics S.A.

Recruiting

Prospective Multicenter Study With the Endomina® Triangulation Platform (PRETTi)

Obesity

Belgium
Ryvu Therapeutics SA

Recruiting

RVU120 (SEL120) in Patients With Relapse/Refractory Metastatic or Advanced Solid Tumors

Advanced Solid Tumor

Spain, Poland
Cerenis Therapeutics, SA

Completed

Exploratory Study of Plaque Regression (EXPRESS)

Heterozygous Familial Hypercholesterolemia

Canada
SeneXta Therapeutics SA

Completed

Safety and Pharmacokinetics of SNX-001 in Healthy Aged Volunteers

Safety

Germany
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 for Treatment of Relapsed/Refractory AML (RIVER-52)

Acute Myeloid Leukemia (AML) | High-risk Myelodysplastic Syndrome

Italy, Poland
Domain Therapeutics SA

Recruiting

DT-9081 Study in Participants With Advanced, Recurrent or Metastatic Solid Tumours (EPRAD)

Solid Tumor, Adult

France, Belgium
Ryvu Therapeutics SA

Not yet recruiting

RVU120 in Patients With Intermediate or High-risk, Primary or Secondary Myelofibrosis (POTAMI-61)

Myelofibrosis

Italy, Poland
Ryvu Therapeutics SA

Recruiting

Safety and Efficacy of RVU120 Combined With Venetoclax for Treatment of Relapsed/Refractory AML (RIVER-81)

Acute Myeloid Leukemia

Spain, France, Poland, Italy
Ryvu Therapeutics SA

Active, not recruiting

RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome

Acute Myeloid Leukemia | High-risk Myelodysplastic Syndrome

United States, Poland
Cerenis Therapeutics, SA

Terminated

CER-001 Therapy as a Novel Approach to Treat Genetic Orphan Diseases (TANGO)

Familial Hypoalphalipoproteinemia

France, United States, Belgium, Canada, Israel, Italy, Netherlands
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Plaque Volume in Homozygous Familial Hypercholesterolemia (HoFH) Subjects (MODE)

Homozygous Familial Hypercholesterolemia

United States, Canada, Italy, Netherlands, United Kingdom
Cerenis Therapeutics, SA

Completed

Effect of CER-001 on Atherosclerosis in Acute Coronary Syndrome (ACS) Patients - Efficacy and Safety: The CHI SQUARE Trial (CHI SQUARE)

Acute Coronary Syndrome

Canada, United States, France, Netherlands
Bone Therapeutics S.A
ICON plc

Recruiting

Study to Assess the Efficacy and Safety of Allogeneic Osteoblastic Cells (ALLOB®) Single Implantation in Tibial Fracture (ALLOB-TF2)

Tibial Fracture

Belgium, Czechia, France, Germany, Hungary, Poland, Spain
Cross Research S.A.
Zambon SpA

Completed

Riluzole Orodispersible Film Replicate Bioavailability

Bioequivalence

Switzerland
Zambon SpA
Cross Research S.A.

Completed

Drug Interaction Study of Safinamide and a BCRP Substrate, Diclofenac, Concomitantly Administered to Healthy Volunteers

Healthy

Switzerland
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Study of Setanaxib Co-Administered With Pembrolizumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck (SCCHN)

Squamous Cell Carcinoma of Head and Neck

Spain, France, United States, Germany, Italy, Poland, United Kingdom
Cross Research S.A.
Zambon SpA

Completed

Safinamide Steady State Interaction With Rosuvastatin

Healthy

Switzerland
Calliditas Therapeutics Suisse SA

Active, not recruiting

A Trial of Setanaxib in Patients With Primary Biliary Cholangitis (PBC) and Liver Stiffness (TRANSFORM)

Primary Biliary Cholangitis | Liver Stiffness

United States, Spain, France, Australia, Israel, Canada, Switzerland, Italy, New Zealand, Germany, Poland, Greece, United Kingdom, Belgium, Austria, Czechia, Hungary, Sweden
Grifols Therapeutics LLC
Instituto Grifols, S.A.

Recruiting

Efficacy and Safety of Fanhdi®, a High-purity Von Willebrand Containing FVIII Concentrate, in Pediatric Patients With Von Willebrand Disease

Von Willebrand Disease

Spain
Instituto Grifols, S.A.

Terminated

Study of the Efficacy and Safety of Immune Globulin Intravenous (Human) Flebogamma® 5% DIF in Patients With Post-polio Syndrome (FORCE)

Post-polio Syndrome

United States, Denmark, Spain, Germany, Poland, Canada, Czechia, Italy, Netherlands

Clinical Trials Sponsored by SFA Therapeutics

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cyprus

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations